Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms OSERO study
Most Recent Events
- 20 Jan 2024 Results (n=455) investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival presented at the 2024 Gastrointestinal Cancers Symposium
- 02 Sep 2020 Status changed from not yet recruiting to recruiting.
- 02 Jul 2020 New trial record